Apogee therapeutics provides pipeline progress and reports second quarter 2024 financial results

Continued advancement of pipeline and execution towards expected milestones, including apg777 16-week proof-of-concept data from the phase 2 part a trial in 2h 2025, apg808 interim phase 1 data in 4q 2024, and apg990 phase 1 trial initiation in healthy volunteers accelerated to 3q 2024
APG Ratings Summary
APG Quant Ranking